Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Merck Wins EU Approval for ENFLONSIA to Protect Infants from RSV
Merck & Co., Inc. announced that the European Commission has approved ENFLONSIA (clesrovimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. This preventive, long-acting monoclonal antibody provides up to five months of protection and is now approved for marketing across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. ENFLONSIA has also been approved in the U.S., Canada, Switzerland, and other markets, with Merck continuing to seek approvals globally.